Pharmacological treatment of idiopathic pulmonary fibrosis – preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pharmacological treatment of idiopathic pulmonary fibrosis – preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine

Published:2015-01-01 Issue:1 Volume:2 Page:26385
ISSN:2001-8525
Container-title:European Clinical Respiratory Journal
language:en
Short-container-title:European Clinical Respiratory Journal

Author:

Myllärniemi Marjukka¹,Kaarteenaho Riitta²³⁴⁵

Affiliation:

1. Department of Pulmonary MedicineHelsinki University Central Hospital, Heart and Lung Center and the University of Helsinki, Helsinki, Finland

2. Department of Internal MedicineRespiratory Diseases, Institute of Clinical Medicine, University of Oulu, Oulu, Finland

3. Medical Research Center Oulu, Respiratory Research Unit, Oulu University Hospital, Oulu, Finland

4. Unit of Medicine and Clinical ResearchPulmonary Division, University of Eastern Finland, Kuopio, Finland

5. Division of Respiratory MedicineCenter for Medicine and Clinical Research, Kuopio University Hospital, Kuopio, Finland

Publisher

Informa UK Limited

Subject

Pulmonary and Respiratory Medicine

Link

https://www.tandfonline.com/doi/pdf/10.3402/ecrj.v2.26385

Reference62 articles.

1. Ahluwalia N, Shea BS, Tager AM. New therapeutic targets in idiopathic pulmonary fibrosis: aiming to rein in runaway wound healing responses. Am J Respir Crit Care Med. 2014; 190: 867–78. [PubMed Abstract].

2. Randomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis

3. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005; 171: 1040–7. [PubMed Abstract].

4. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010; 35: 821–9. [PubMed Abstract].

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enzyme-like nanoparticle–engineered mesenchymal stem cell secreting HGF promotes visualized therapy for idiopathic pulmonary fibrosis in vivo;Science Advances;2024-08-23

2. Obesity-induced fibrosis in osteoarthritis: pathogenesis, consequences and novel therapeutic opportunities;Osteoarthritis and Cartilage Open;2024-08

3. LPA1 antagonist-derived LNPs deliver A20 mRNA and promote anti-fibrotic activities;Nano Research;2024-06-27

4. Preparation and evaluation of inhalable S-allylmercapto-N-acetylcysteine and nintedanib co-loaded liposomes for pulmonary fibrosis;European Journal of Pharmaceutical Sciences;2024-06

5. Engineered extracellular vesicles carrying let-7a-5p for alleviating inflammation in acute lung injury;Journal of Biomedical Science;2024-03-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3